How subcutaneous amivantamab approval in Europe could reshape EGFR-mutated NSCLC treatment workflows
EU approves subcutaneous amivantamab for expanded EGFR lung cancer dosing. Discover what this changes for clinicians and health systems.
Can PharmAla’s three year stability program de risk MDMA distribution challenges?
PharmAla will generate three year stability data for LaNeo MDMA. Discover how this could shape packaging, regulation, and commercialization.